key: cord-0011601-wul6fp8n
authors: Jain, Amit; Doyle, D. John
title: Stages or phenotypes? A critical look at COVID-19 pathophysiology
date: 2020-05-18
journal: Intensive Care Med
DOI: 10.1007/s00134-020-06083-6
sha: a1f8eac3c8425160d22b87de2e142ef3041dab00
doc_id: 11601
cord_uid: wul6fp8n

nan

proposed pulmonary vasoplegia as a key mechanism for the onset of severe hypoxia, but failed to give any plausible mechanism for this vasoplegia. We instead propose a 'epithelial-endothelial crosstalk' hypothesis that may provide a better explanation for the different stages of COVID-19 pneumonia:

i. Downregulation of ACE-2 on type II alveolar epithelial cells SARS-CoV-2 enters the type II alveolar epithelial cells following binding of its spike protein to the ACE-2 receptor. This causes ACE-2 downregulation on the alveolar epithelium. Of note, SARS-CoV-2 seems to produce little or no direct cytopathic changes in the pulmonary epithelium [3] .

ii. Endothelial dysfunction The downregulation of ACE-2 on pulmonary epithelium results in unopposed effects of ACE-1 on the pulmonary capillary endothelial cells. Consequently, the level of protective ACE2-Ang 1-7-mas-R activity is reduced, while the level of harmful ACE 1-Ang II-AT1-R activity is increased. Possibly, the earliest deleterious effect of ACE 1-Ang II-AT1-R overactivity is the release of a potent vasoconstrictor, endothelin-1, from the pulmonary endothelium. ACE2-Ang 1-7-mas-R mediated constitutive endothelial nitric oxide (NO) synthase activation, and NO release is inhibited [4] . The intense pulmonary vasoconstriction so developed is severe, but uneven and results in the recruitment of capillary beds with relatively less vasoconstriction. As a result, the shunt fraction is increased and severe hypoxia ensues. As the disruption of the alveolar-capillary barrier progresses, proteins, fibrin, cells and fluid leak into the alveolar space, resulting in bilateral patchy ground glass opacities on CT scan.

While patient-self-inflicted lung injury (P-SILI) is common, as a sole underlying mechanism for the progression of COVID-19 pneumonia to severe ARDS, it appears to be unlikely, especially, when early invasive mechanical ventilation policies are now largely adopted.

We hypothesize that 'endothelial-epithelial' interaction plays a major role in the disease progression: Following alveolar-capillary membrane disruption, SARS-CoV-2 enters the pulmonary capillaries and directly infects the pulmonary endothelial cells via ACE-2 protein on the luminal surfaces. As a result, endothelial cells assume a 'proinflammatory'/'procoagulant' phenotype. This accelerates Fas-induced apoptosis of alveolar epithelial and endothelial cells and orchestrates the cytokine storm and the progression of COVID-19 to ARDS [5] .

The above hypothesis has treatment implications that warrant further investigation. It appears that high PEEP therapy, while preventing P-SILI, can increase shunt fraction; early intubation may not prevent a transition to ARDS, and early inhaled NO, steroids and anticoagulation therapy may be potentially helpful.

Funding Support was provided solely from institutional and/or departmental sources.

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

China Novel Coronavirus I, Research T (2020) A novel coronavirus from patients with pneumonia in China

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities

The authors declare no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Accepted: 30 April 2020